Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* Eradication of *Helicobacter pylori* infection (in combination with antibiotics)
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily.
* Maintenance: 20-40 mg once daily.
* **Hypersecretory Conditions:** 40 mg orally or intravenously twice daily.
* Dose may be increased as needed. Usual range 80-160 mg daily divided every 12 hours.
* ***H. pylori* Eradication (Triple Therapy):** 40 mg orally twice daily for 7-14 days with clarithromycin and amoxicillin or metronidazole.
## Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **12 to 16 years:** 40 mg orally once daily.
* **5 to 11 years:** 20 mg orally once daily.
* **2 to 16 years (alternative for severe erosive esophagitis):** 40 mg orally once daily.
* **Note:** Dosing for pediatric use in hypersecretory conditions or *H. pylori* eradication may follow specific institutional protocols or specialist guidance due to limited data.
## Dose Adjustments
No dose adjustment is typically required for hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, Vitamin B12 deficiency, potential for fundic gland polyps.
## Key Drug Interactions
* **Warfarin:** May increase INR and prothrombin time. Monitor INR closely.
* **Methotrexate:** May increase methotrexate levels, potentially leading to toxicity. Consider withholding pantoprazole during methotrexate treatment.
* **Drugs dependent on gastric pH for absorption:**
* **Ketoconazole, Itraconazole, Posaconazole, Erlotinib, Ritonavir:** Absorption may be decreased.
* **Rilpivirine:** Concomitant use is contraindicated.
* **Cyanocobalamin (Vitamin B12):** Reduced absorption.
## Monitoring
* Electrolytes (especially magnesium) with prolonged therapy or in patients taking diuretics.
* Bone mineral density with long-term use.
* Signs and symptoms of *C. difficile* infection.
* INR if co-administered with warfarin.
## Clinical Pearls
* Administer 30-60 minutes before a meal for optimal efficacy.
* Intravenous formulation is a potential substitute for oral administration when oral intake is not possible. Revert to oral therapy as soon as feasible.
* Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, and hypomagnesemia. Use the lowest effective dose for the shortest duration necessary.
---
**Disclaimer:** This information is a concise summary and does not replace a thorough review of the current Prescribing Information or consultation with a healthcare provider. Always verify drug information with up-to-date resources before use.
